BICO (BICO) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
19 Aug, 2026Executive summary
Net sales in Q2 2026 reached SEK 336.1m, up 3.7% year-over-year, with organic growth of 7.3%.
Adjusted EBITDA improved to SEK 20.1m, with a 6% margin, reflecting a 21 percentage point improvement from the prior year.
Leadership transition announced: Anders Fogelberg appointed President and CEO effective September 1, 2026, succeeding Maria Forss, who will remain as Senior Advisor for a quarter.
Profitability improved significantly, but the company still reported a net loss of SEK -37.2m for the quarter.
Major restructuring and transformation programs are ongoing to enhance efficiency and streamline operations.
Financial highlights
Q2 sales reached SEK 336 million, with 7% organic growth in local currencies and 4% total growth due to currency headwinds.
Adjusted EBITDA margin was 6%, up from -15% in Q2 2025.
Gross profit margin improved to 59.3% from 43.9% last year, driven by favorable product mix and higher share of direct sales.
Cash flow from operating activities was SEK -53 million, mainly due to negative net working capital changes.
Cash reserves at period end were SEK 628 million, with SEK 57 million restricted.
Outlook and guidance
Management expresses confidence in gradual market recovery, though U.S. academic end markets remain soft due to reduced funding.
Business is seasonal, with typically stronger performance in the second half of the year.
No formal forecasts provided for 2026.
Restructuring project launched in Q1 2026 is progressing as planned, supporting profitability improvements.
Long-term supply and license agreements signed post-quarter are expected to positively impact Q3 revenue.
Latest events from BICO
- 11% organic growth, improved EBITDA, and restructuring drive savings and liquidity boost.BICO
Q1 2026 - Lab Automation rebounded in Q4, but full-year sales fell and impairments weighed on results.BICO
Q4 2025 - Q3 2025 delivered strong organic growth, major divestments, and a strengthened cash position.BICO
Q3 2025 - Sales fell and losses deepened, but divestments improved liquidity and strategic focus.BICO
Q2 2025 - Q3 sales and profitability declined, but strategic actions and new strategy target recovery.BICO
Q3 2024 - Lab automation, integrated workflows, and recurring revenue drive growth and strategic focus.BICO
CMD 2024 - Stable sales and improved margins, but market volatility and regional demand challenges persist.BICO
Q2 2024 - Net sales dropped 17.3% in Q1, but divestments will drive a net cash position in Q2.BICO
Q1 2025 - Profitability and cash flow surged in Q4 2024 as debt was reduced and Nanoscribe divested.BICO
Q4 2024